Old Mutual Global Investors UK Ltd. decreased its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 36.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 70,289 shares of the medical research company’s stock after selling 40,162 shares during the quarter. Old Mutual Global Investors UK Ltd.’s holdings in Amgen were worth $12,105,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in AMGN. Financial Advisory Service Inc. increased its holdings in shares of Amgen by 0.3% in the second quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock valued at $340,000 after purchasing an additional 5 shares during the last quarter. Capital Advisors Ltd. LLC grew its stake in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock valued at $190,000 after acquiring an additional 7 shares in the last quarter. Ballentine Partners LLC grew its stake in shares of Amgen by 0.3% in the second quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock valued at $620,000 after acquiring an additional 9 shares in the last quarter. Hudock Capital Group LLC grew its stake in shares of Amgen by 0.5% in the second quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock valued at $330,000 after acquiring an additional 10 shares in the last quarter. Finally, Investment Partners Ltd. OH ADV grew its stake in shares of Amgen by 0.5% in the second quarter. Investment Partners Ltd. OH ADV now owns 2,192 shares of the medical research company’s stock valued at $377,000 after acquiring an additional 11 shares in the last quarter. 78.38% of the stock is currently owned by hedge funds and other institutional investors.
Amgen, Inc. (NASDAQ AMGN) opened at $178.67 on Wednesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 6.07 and a quick ratio of 5.72. Amgen, Inc. has a twelve month low of $138.83 and a twelve month high of $191.10. The stock has a market capitalization of $129,712.96, a price-to-earnings ratio of 14.20, a P/E/G ratio of 2.59 and a beta of 1.36.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Friday, November 17th will be paid a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date is Thursday, November 16th. Amgen’s payout ratio is 41.63%.
Amgen declared that its board has authorized a share buyback plan on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to buy shares of its stock through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its shares are undervalued.
Several research firms recently weighed in on AMGN. Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $199.00 price objective for the company in a research report on Friday, October 27th. Bank of America increased their target price on shares of Amgen to $210.00 and gave the stock a “buy” rating in a report on Thursday, October 5th. Barclays increased their target price on shares of Amgen from $180.00 to $190.00 and gave the stock an “equal weight” rating in a report on Friday, October 13th. Oppenheimer reissued a “buy” rating and issued a $203.00 target price on shares of Amgen in a report on Thursday, September 7th. Finally, Royal Bank Of Canada assumed coverage on Amgen in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $190.22.
In related news, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $171.58, for a total value of $261,659.50. Following the completion of the sale, the executive vice president now directly owns 57,631 shares of the company’s stock, valued at approximately $9,888,326.98. The disclosure for this sale can be found here. Insiders have sold a total of 7,050 shares of company stock worth $1,239,673 over the last quarter. Company insiders own 0.19% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Old Mutual Global Investors UK Ltd. Sells 40,162 Shares of Amgen, Inc. (NASDAQ:AMGN)” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://stocknewstimes.com/2017/12/06/amgen-inc-amgn-holdings-trimmed-by-old-mutual-global-investors-uk-ltd.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.